Austria imposed a lockdown on people unvaccinated against the coronavirus on November 15 as winter approaches and infections rise across Europe, with Germany considering tighter curbs and Britain expanding its booster program to younger adults.
Global Covid-19 cases surpassed 250 million on November 8 as some countries in eastern Europe experience record outbreaks, even as the Delta variant surge eases and many countries resume trade and tourism.
Europe registered a 55 percent rise in Covid-19 cases in the last four weeks, despite the availability of vaccines, which should serve as a “warning shot” to other regions, World Health Organization (WHO) officials said on November 4.
EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced its membership in the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), the region’s principal trade association for small to medium-sized companies in the pharmaceutical, biotech and medtech industries.
The Greater Than One (GTO) Group announced the introduction of a new operating model to better serve clients outside the United States. Referred to as OUS (Outside United States) On-Demand, the new model will bring the same level of service innovation and value creation abroad as US-based clients experience today.
A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of Covid-19, researchers suggested in a report. In other news, Gilead Sciences Inc.’s intravenous antiviral drug remdesivir helped keep high-risk Covid-19 patients out of the hospital in a randomized trial.
A study out of Oxford University’s Leverhulme Centre for Demographic Science found that the Covid-19 pandemic has resulted in the largest drop in life expectancy in western Europe since World War II.
The Covid-19 pandemic reduced life expectancy in 2020 by the largest amount since World War Two, according to a study published on Sept. 27 by Oxford University, with the life expectancy of American men dropping by more than two years.
Paris-based Jeito Capital announced the final close on its first fund, which is the largest venture capital fund in Europe focused on life sciences.
Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, which are rare progressive kidney diseases that are leading causes of end-stage kidney disease.